Psychiatric Genomics, inc.
Mental illness affects millions of patients and has been shown to have multiple genetic components. The interaction of environmental factors, such as stress, with the expression of genetic susceptibilities has hampered the development of novel and effective drug treatments. A new approach is described that can discover novel classes of drugs for the treatment of the underlying causes of these diseases rather than their symptoms. This approach screens drug candidates according to their ability to alter the expression of multiple genes in a multiparameter high-throughput screening assay (MPHTS SM) that does not require a prori knowledge of the targets of screening assays. Clinical development of drug candidates will be pursued through partnerships with pharmaceutical companies and/or large biotechnology companies.
Palfreyman
Michael G
MG
Psychiatric Genomics, Inc., 19 Firstfield Rd, Gaithersburg, MD 20878, USA. mpalfreyman@psygenomics.com
D004353:Drug Evaluation, Preclinical; D023281:Genomics / Q000191:economics*; D006801:Humans; D007221:Industry; D001523:Mental Disorders / Q000235:genetics* / Q000628:therapy*; D010597:Pharmacogenetics / Q000191:economics*; D011619:Psychotropic Drugs / Q000494:pharmacology*
D011619:Psychotropic Drugs